SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as escalating geopolitical tensions in the Middle East, driven by reports of US-Israeli strikes on Iran and subsequent retaliations, fuel widespread community discussion about potential oil supply disruptions, particularly regarding the Strait of Hormuz. Community sentiment is sharply divided between those anticipating a significant price surge and others expecting a rapid "sell the news" reversal.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending amidst escalating US-Iran conflict, with strikes on Gulf infrastructure and threats to the Strait of Hormuz fueling widespread fears of global oil supply disruptions and significant crude price surges. The community is actively discussing a flight to energy assets, positioning the sector for strong momentum even as broader markets anticipate risk-off sentiment.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

INDO is trending amidst escalating Middle East tensions, with community chatter focused on US/Israel strikes in Iran and potential disruptions to the critical Strait of Hormuz, fueling expectations of a massive oil price surge and a short squeeze for this low-float energy play.

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.

MediWound Ltd

MediWound is trending as investors eagerly anticipate a potential BARDA contract for its burn treatment NexoBrid, which recently showed strong efficacy in blast injuries, alongside promising advancements for its EscharEx chronic wound therapy. This momentum, including institutional interest and buyout speculation, is driving conversation despite polarized views on the stock's ability to break through current trading ranges.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is seeing strong conversation driven by its rapidly expanding ecosystem, marked by new integrations and user adoption, alongside significant whale investments. The community is highly optimistic about its advanced Layer 1 technology, high staking yields, and perceived resilience during market fluctuations, positioning it as a promising long-term crypto play.

The RealReal, Inc. is an online marketplace for consigned luxury goods, which engages in the consignment of luxury goods across multiple categories, including women's, men's, kids, jewelry, watches, home, and art. It sells pieces from designers such as Chanel, Christian Louboutin, Gucci, Hermes, Louis Vuitton, Prada, Celine, Jimmy Choo, Burberry, and Valentino. The company was founded by Julie Wainwright and Marcy Carmack on March 29, 2011 and is headquartered in San Francisco, CA.

Therealreal Inc

The RealReal is trending following consistently strong financial results, including adjusted EBITDA profitability and positive free cash flow, which the community sees as an inflection point. Analysts are upgrading ratings, while discussions also revolve around AI-driven efficiencies, high short interest, and the broader growth of the luxury resale market.

Vanguard Group, Inc. - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending amidst heightened market uncertainty driven by Federal Reserve policy, geopolitical developments, and ongoing debates about the sustainability of valuations in the tech sector. Despite some community calls for a significant correction, many investors continue to favor VOO for its broad market exposure and long-term stability.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending amid enthusiasm for positive Phase 3 clinical trial results for its HER2-positive breast cancer drug and encouraging lung cancer therapy data, fueling community discussions about its oncology pipeline and strategic pivot, even as some debate recent analyst upgrades against news of a partner offloading its stake.

River is building a chain-abstraction stablecoin system that enables cross-chain collateral, yield, and liquidity—all without bridging.   Powered by the omni-CDP stablecoin satUSD, users can earn, leverage, and scale across different ecosystems natively.   River features the first omni-CDP module that allows users to collateralize assets on Chain A and mint stablecoin satUSD on Chain B—without bridging the assets.

River

RIVER CRYPTO is generating buzz driven by strategic funding, high-profile crypto endorsements, and potential major exchange listings. The community actively debates its extreme volatility and innovative stablecoin abstraction system amidst both bullish predictions and "pump and dump" concerns.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Crane Harbor Acquisition Corp. - Ordinary Shares - Class A

Crane Harbor Acquisition Corp.

CHAC is gaining attention ahead of its imminent SPAC merger with Xanadu, a Canadian photonic quantum computing leader. The community is discussing Xanadu's pioneering room-temperature technology and its widely used PennyLane software, with many anticipating a significant rally for this unique pure-play in the quantum sector, though some note valuation concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Estimates Arvinas' Q1 Earnings (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - HC Wainwright cut their Q1 2026 earnings per share (EPS) estimates for shares of Arvinas in a report issued on Wednesday, February 25th. HC Wainwright...

Arvinas (NASDAQ:ARVN) CAO David Loomis Sells 1,108 Shares

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) CAO David Loomis sold 1,108 shares of the firm's stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $12.16...

Arvinas (NASDAQ:ARVN) CEO Randy Teel Sells 4,786 Shares

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) CEO Randy Teel sold 4,786 shares of the firm's stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $12.16, for a...

5 Analysts Assess Arvinas: What You Need To Know

Arvinas (NASDAQ:ARVN) Trading Up 9% - Still a Buy?

Arvinas (NASDAQ:ARVN) Shares Up 9% - Here's What Happened...

Arvinas (NASDAQ:ARVN) Receives Overweight Rating from Piper Sandler

Piper Sandler reaffirmed an "overweight" rating and set a $20.00 price target (up from $16.00) on shares of Arvinas in a research note on Wednesday...

Arvinas, Inc. (NASDAQ:ARVN) Given Average Rating of "Hold" by Brokerages

Shares of Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) have earned a consensus recommendation of "Hold" from the twenty analysts that are covering the company, MarketBeat.com reports. Two equities...

Arvinas (ARVN) Q4 2025 Earnings Call Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Arvinas Q4 Earnings Call Highlights

Arvinas (NASDAQ:ARVN) executives used the company's fourth-quarter and full-year 2025 earnings call to outline a strategy centered on advancing four Phase 1 clinical programs and preparing for...

Arvinas (NASDAQ:ARVN) Shares Gap Down After Earnings Miss

Arvinas (NASDAQ:ARVN) Shares Gap Down After Earnings Miss...

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Arvinas Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Current Price	$13.27
Prev Close	$13.38
Open	$13.07
Dividend Yield	0.00%
50-Day Moving Average	$12.45
Beta	1.37
Avg. Volume	778,397.30
PE Ratio	-10.91

52-Week High	$18.93
52-Week Low	$5.90
Market Capitalization	$848.76M
EPS (Annual)	-$1.14
Price to Book	1.94
Revenue Per Employee	$1.07M

ARVN
Arvinas Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ARVN News

ARVNArvinas Inc